Clinical trials
Relapsed clinical trials
Below are recruiting relapsed clinical trials, each written for real people, not researchers. We’re tracking 906 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06643585RecruitingPhase 3
Comparing T-DXd to standard therapy for molecular relapse in early breast cancer
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
UlmAges 18–75 - NCT06644118RecruitingPhase 1
Study of OL-101 for people with relapsed or refractory multiple myeloma
This trial tests a new treatment called OL-101 for people whose multiple myeloma has come back or stopped responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. It aims to see if OL-101 can help control the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06649253Recruiting
CD9 Gene and Relapse in Childhood B-ALL Study
This study looks at how a gene called CD9 might affect relapse in children with B-ALL. It involves extra blood or bone marrow tests to understand why some children relapse.
AngersAges birth–17 years - NCT06649227RecruitingPhase 1
CD19 CAR-T cells for hard-to-treat AML
This study tests a new type of immunotherapy (CAR-T cells that target CD19) for adults with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It aims to see if these CAR-T cells are safe and can help control the leukemia.
LilleAges 18 years+ - NCT06651229RecruitingPhase 1
Study of JNJ-90189892 for blood cancers
This trial tests a new drug, JNJ-90189892, for people with certain types of blood cancers (acute myeloid leukemia or higher-risk myelodysplastic neoplasms) that have come back or not responded to treatment. The goal is to see if the drug is safe and effective.
ConcordAges 18 years+ - NCT06651606Recruiting
Preventing relapse of problem behavior in kids with disabilities
This trial tests a new approach to help children and young adults with intellectual and developmental disabilities reduce problem behaviors and avoid relapses. It uses ideas from behavioral economics to find what works best for each person.
Auburn, AlabamaAges 6–21 - NCT06659653RecruitingEarly Phase 1
PRG-2302 for relapsed or hard-to-treat B-cell acute lymphoblastic leukemia
This trial tests a new drug called PRG-2302 for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not responded to standard treatments. The goal is to see if PRG-2302 is safe and can help control the disease.
Jinzhou, HubeiAges 18–70 - NCT06660368RecruitingPhase 2
A study of a drug combo for relapsed or refractory AML
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Tampa, FloridaAges 18–80 - NCT06663098RecruitingPhase 2
Atezolizumab and chemo again for relapsed small cell lung cancer
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
Aviano (PN)Ages 18 years+ - NCT06663111Recruiting
Rituximab and Ocrelizumab levels in Multiple Sclerosis
This trial looks at two medicines, rituximab and ocrelizumab, in the blood of people with multiple sclerosis. It only includes people who are already in another study called OVERLORD-MS and can give blood samples on a schedule.
Bergen, VestlandAges 18–60 - NCT06680752RecruitingPhase 1/Phase 2
A car-t cell therapy trial for AML or MDS
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
Charlotte, North CarolinaAges 18 years+ - NCT06682130RecruitingPhase 2
Glofitamab before stem cell transplant for relapsed DLBCL
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
Suzhou, JiangsuAges 18–70 - NCT06687772RecruitingPhase 2
Preventing brain relapse in high-risk lymphoma with stem cell transplant
This trial tests if high doses of chemotherapy (thiotepa and carmustine) followed by a stem cell transplant from your own cells can prevent lymphoma from coming back in the brain or spinal cord. It's for people with aggressive lymphoma that has a higher risk of spreading to the central nervous system.
St Louis, MissouriAges 18–75 - NCT06693973RecruitingEarly Phase 1
AcNK-Sup003 cell therapy for relapsed B-cell lymphoma
This early-phase trial tests a new immune cell treatment called AcNK-Sup003 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior therapy. The goal is to see if it is safe and effective.
Wuhan, HubeiAges 18 years+ - NCT05160584Recruiting
Real-world treatment study for relapsed or refractory myeloma
This study follows people with multiple myeloma that has come back or stopped responding to treatment, and looks at how current care is used in real life. It may include people starting talquetamab, and aims to understand outcomes and treatment patterns outside of strict experimental settings.
LeobenAges 18 years+ - NCT05091424RecruitingPhase 1
Mosunetuzumab with or without venetoclax for CLL
This Phase 1 study tests whether mosunetuzumab alone or with venetoclax is safe and effective for people with chronic lymphocytic leukemia (CLL) that came back or did not respond to prior treatment. It may help by controlling the CLL immune system response while also studying dosing and side effects.
Rochester, MinnesotaAges 18 years+ - NCT03874052RecruitingPhase 1
Ruxolitinib plus venetoclax and azacitidine for relapsed AML
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
Columbus, OhioAges 18 years+ - NCT05139017RecruitingPhase 2/Phase 3
Test drug Zilovertamab vedotin with standard care for lymphoma
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
Glendale, ArizonaAges 18 years+ - NCT07384715RecruitingPhase 1
GEN3018 for AML or high-risk MDS
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
AarhusAges 18 years+ - NCT06641271Enrolling by invitation
Vagus nerve stimulation with hand exercises for MS
This study tests if vagus nerve stimulation (a mild electrical pulse on the ear) combined with hand exercises can help repair the protective coating of your nerves and improve hand function in multiple sclerosis.
Aurora, ColoradoAges 18–70 - NCT06709495RecruitingPhase 1/Phase 2
PEEL-224 with chemo for teens and young adults with sarcoma
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 12–49 - NCT06713837RecruitingPhase 3
Comparing treatments for relapsed or hard-to-treat AML
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
BrnoAges 18 years+ - NCT06715436Recruiting
Ketogenic diet for multiple sclerosis
This study tests whether a ketogenic diet can help people with multiple sclerosis. You would follow a special high-fat, low-carb diet for a period, and the researchers will check its effects on your symptoms and overall health.
PaviaAges 18–60 - NCT06725524RecruitingPhase 1
New drug for B-cell lymphoma that returned after treatment
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
ShanghaiAges 18–70
Hear when a new Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed?
- Yes. Clin2 currently lists 906 recruiting relapsed studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.